Biotech reverse mergers growing amid improving market conditions

Biotech reverse mergers are on track to tally their largest number in recent years, buoyed by the forces of industry’s current transition moment in which there remains an large number of distressed public companies weighing their options at the same time as the prospect of a thawing public market has more private company executives willing to test the waters. 

Drug developers have announced at least 10 reverse mergers so far in 2023. That’s on par with the total number seen in all of 2022. If the trend continues at this pace, the year’s total would surpass that of last few years...